Skip to main content

Table 6 Live birth outcomes of the 865 ICSI cycles.

From: A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection

  hMG HP-hMG r-hFSH p value
Cycles with live births, n 73 107 71  
   Single, n (%) 50 (68.5) 68 (63.5) 46 (64.8) 0.57
   Twins, n (%) 18 (24.7) 34 (31.8) 22 (31.0) 0.59
   Triplets, n (%) 5 (6.8) 5 (4.7) 3 (4.2) 0.89
Mean gestational age, weeks (± SD)     
   Single 36.5 (± 3.6)a 38.1 (± 2.1)b 38.3 (± 2.3)c 0.01
(a vs b, c)
   Twins 35.0 (± 0.8)a 35.1 (± 3.0)b 37.3 (± 2.7)c 0.03
(a, b vs c)
   Triplets 29.3 (± 3.5)a 31.1 (± 3.4)b 34.0 (± 0.0)c 0.03
(a vs c)
Mean weight, g (± SD)     
   Single 2882 (± 703) 3064 (± 470) 3024 (± 334) 0.09
   Twins 2352 (± 436)a 2067 (± 614)b 2230 (± 715)c 0.01
(a vs b)
   Triplets 1250 (± 329)a 1470 (± 448)b 1747 (± 196)c 0.03
(a vs c)
  1. Cycles with live births in relation to the parity and gestational outcomes of the babies from 865 ICSI cycles with menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH) used for COH. Overall and parity-stratified outcomes are presented.
  2. COH, controlled ovarian hyperstimulation; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; r-hFSH, recombinant human follicle-stimulating hormone; SD, standard deviation.